Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Open for enrollment

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

To evaluate the safety and tolerability of once-daily, oral administration of resmetirom for 52 weeks.

Principal Investigator	Fernando Membreno, MD
Co-PI	John Rodriguez
Sponsor	Madrigal Pharmaceuticals, Inc.
Type of Trial	Interventional

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390